48.13

1.63% 0.77

After Hours: 48.13

Ultragenyx Pharmaceutical Inc (RARE)

Overview News Price History Option Chain Financials Why RARE Down? Discussions Forecast Stock Split

Ultragenyx Pharmaceutical Inc stock is traded at $48.13, with a volume of 291.69K. It is up +1.63% in the last 24 hours and down -10.57% over the past month. Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.

Previous Close:

$47.36

Open:

$47.69

24h Volume:

291.69K

Relative Volume:

0.42

Market Cap:

$4.39B

Revenue:

$522.75M

Net Income/Loss:

$-558.99M

P/E Ratio:

-5.3657

EPS:

-8.97

Net Cash Flow:

$-492.48M

1W Performance:

+3.73%

1M Performance:

-10.57%

6M Performance:

+19.31%

1Y Performance:

+24.66%

1-Day Range:

$46.96

$48.24

1-Week Range:

$45.47

$48.62

52-Week Range:

$37.02

$60.37

Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile

Name

Ultragenyx Pharmaceutical Inc

Sector

Healthcare (1200)

Industry

Biotechnology (682)

Phone

415-483-8800

Address

60 LEVERONI COURT, NOVATO, CA

Employee

1,276

Twitter

Next Earnings Date

2024-11-05

Latest SEC Filings

RARE's Discussions on Twitter

Compare RARE with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RARE Ultragenyx Pharmaceutical Inc	48.13	4.39B	522.75M	-558.99M	-492.48M	-8.97
VRTX Vertex Pharmaceuticals Inc	464.56	119.70B	10.63B	-479.80M	-1.35B	13.33
REGN Regeneron Pharmaceuticals Inc	754.87	82.75B	13.85B	4.65B	3.32B	35.06
ARGX Argen X Se Adr	614.59	36.73B	1.86B	-40.29M	-1.28B	-4.16
ALNY Alnylam Pharmaceuticals Inc	253.74	32.53B	2.09B	-332.26M	16.06M	-4.14
BNTX Biontech Se Adr	120.72	28.50B	3.30B	-501.07M	1.03B	11.54

Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-06-24	Upgrade	Goldman	Neutral → Buy
Apr-22-24	Initiated	RBC Capital Mkts	Outperform
Dec-08-23	Initiated	Wells Fargo	Overweight
Jun-14-23	Resumed	Credit Suisse	Outperform
Jun-06-23	Upgrade	Evercore ISI	In-line → Outperform
Apr-26-23	Initiated	Cantor Fitzgerald	Overweight
Jan-18-23	Resumed	Canaccord Genuity	Buy
Dec-30-22	Resumed	H.C. Wainwright	Buy
Nov-03-22	Upgrade	Robert W. Baird	Neutral → Outperform
Oct-13-22	Upgrade	Guggenheim	Neutral → Buy
Aug-01-22	Downgrade	Evercore ISI	Outperform → In-line
Mar-16-22	Upgrade	Credit Suisse	Neutral → Outperform
Feb-11-22	Upgrade	JP Morgan	Neutral → Overweight
Sep-30-21	Initiated	H.C. Wainwright	Buy
Aug-19-21	Initiated	UBS	Sell
Jul-15-21	Initiated	Guggenheim	Neutral
Jun-29-21	Upgrade	BofA Securities	Neutral → Buy
Jun-04-21	Resumed	Robert W. Baird	Neutral
May-06-21	Upgrade	Citigroup	Neutral → Buy
May-06-21	Upgrade	Evercore ISI	In-line → Outperform
Apr-26-21	Resumed	Credit Suisse	Neutral
Mar-02-21	Resumed	Stifel	Buy
Feb-12-21	Downgrade	JP Morgan	Overweight → Neutral
Dec-07-20	Downgrade	Wedbush	Outperform → Neutral
Nov-24-20	Resumed	Evercore ISI	In-line
Nov-12-20	Downgrade	BofA Securities	Buy → Neutral
Aug-02-19	Resumed	Wedbush	Outperform
Mar-27-19	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Feb-22-19	Resumed	Raymond James	Outperform
Jan-02-19	Downgrade	Raymond James	Outperform → Mkt Perform
Nov-08-18	Upgrade	Citigroup	Sell → Neutral
Sep-10-18	Initiated	Morgan Stanley	Equal-Weight
Jun-21-18	Downgrade	Credit Suisse	Outperform → Neutral
May-11-18	Upgrade	Barclays	Equal Weight → Overweight
May-10-18	Initiated	Goldman	Neutral
Apr-18-18	Upgrade	SunTrust	Hold → Buy
Mar-22-18	Resumed	Piper Jaffray	Overweight
Feb-21-18	Reiterated	Stifel	Buy
Jan-22-18	Upgrade	Evercore ISI	In-line → Outperform
Jan-18-18	Initiated	Credit Suisse	Outperform
Dec-05-17	Reiterated	Barclays	Equal Weight
Dec-04-17	Upgrade	Jefferies	Hold → Buy
Sep-14-17	Upgrade	Wedbush	Neutral → Outperform

View All

Ultragenyx Pharmaceutical Inc Stock (RARE) Latest News

Nov 27, 2024

Ultragenyx to Participate in Investor Conferences in December - GlobeNewswire

Nov 27, 2024

Nov 26, 2024

Ultragenyx to Present at Three Major Healthcare Investor Conferences in December | RARE Stock News - StockTitan

Nov 26, 2024

CDKL5 Deficiency Disorder Market Revenue to Expand Significantly by 2034, States DelveInsight Report | Marinus Pharma, Takeda, Zogenix, Inc., UCB, Ultragenyx Pharma - The Globe and Mail

Nov 26, 2024

CDKL5 Deficiency Disorder Market Revenue to Expand - openPR

Nov 26, 2024

Algert Global LLC Boosts Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat

Nov 26, 2024

Massachusetts Financial Services Co. MA Purchases 172,126 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat

Nov 26, 2024

Swiss National Bank Grows Stock Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat

Nov 26, 2024

Nov 25, 2024

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Stock Holdings Boosted by Natixis Advisors LLC - MarketBeat

Nov 25, 2024

Nov 24, 2024

Connor Clark & Lunn Investment Management Ltd. Sells 87,626 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat

Nov 24, 2024

Nov 23, 2024

Top 10 startups in Rare Diseases in Bay Area, United States in Nov, 2024 - Tracxn

Nov 23, 2024

B. Metzler seel. Sohn & Co. Holding AG Takes $1.32 Million Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat

Nov 23, 2024

Nov 22, 2024

Hypophosphatasia Market 2034: Epidemiology Review, Pipeline - openPR

Nov 22, 2024

BNP PARIBAS ASSET MANAGEMENT Holding S.A. Has $40.23 Million Stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat

Nov 22, 2024

Principal Financial Group Inc. Acquires 76,150 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat

Nov 22, 2024

Nov 20, 2024

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Nov 20, 2024

Ultragenyx Grants 20,820 RSUs to New Officers in Four-Year Vesting Plan | RARE Stock News - StockTitan

Nov 20, 2024

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives $86.69 Consensus PT from Analysts - MarketBeat

Nov 20, 2024

Nov 18, 2024

State of New Jersey Common Pension Fund D Has $1.93 Million Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat

Nov 18, 2024

Nov 15, 2024

Osteogenesis Imperfecta Treatment Market 2024-2031: Global - openPR

Nov 15, 2024

Nov 14, 2024

How To Trade (RARE) - Stock Traders Daily

Nov 14, 2024

RTW INVESTMENTS, LP Adjusts Stake in Ultragenyx Pharmaceutical I - GuruFocus.com

Nov 14, 2024

Nov 13, 2024

Ultragenyx Pharmaceutical's SWOT analysis: pipeline progress boosts rare disease stock - Investing.com

Nov 13, 2024

Nov 12, 2024

Ultragenyx posts trial data backing Phase 3 design for Angelman syndrome therapy - MSN

Nov 12, 2024

Ultragenyx Pharmaceutical (NASDAQ:RARE) Receives Buy Rating from Canaccord Genuity Group - MarketBeat

Nov 12, 2024

Ultragenyx: Ready For More Growth After Q3 Earnings Beat (NASDAQ:RARE) - Seeking Alpha

Nov 12, 2024

Mereo BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire

Nov 12, 2024

Nov 11, 2024

Research Analysts Offer Predictions for RARE FY2024 Earnings - MarketBeat

Nov 11, 2024

Nov 10, 2024

Ultragenyx Q3 Loss Narrower Than Expected, Revenues Beat Estimates - MSN

Nov 10, 2024

Nov 09, 2024

Ultragenyx posts data for Angelman syndrome therapy (RARE:NASDAQ) - Seeking Alpha

Nov 09, 2024

Ultragenyx Presents Positive Update on GTX-102 Angelman - GlobeNewswire

Nov 09, 2024

Ultragenyx's Angelman Treatment Shows 80% Patient Improvement in Phase 1/2 Trial | RARE Stock News - StockTitan

Nov 09, 2024

Nov 08, 2024

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 07, 2024

What is HC Wainwright's Estimate for RARE Q1 Earnings? - MarketBeat

Nov 07, 2024

Ultragenyx Pharmaceutical Third Quarter 2024 Earnings: Beats Expectations - Simply Wall St

Nov 07, 2024

Nov 06, 2024

Ultragenyx Pharmaceutical's (RARE) Overweight Rating Reiterated at Cantor Fitzgerald - MarketBeat

Nov 06, 2024

Ultragenyx Pharma stock target raised, retains buy on strong revenue growth - Investing.com India

Nov 06, 2024

HC Wainwright Boosts Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $95.00 - MarketBeat

Nov 06, 2024

Ultragenyx Pharma stock target raised, retains buy on strong revenue growth By Investing.com - Investing.com South Africa

Nov 06, 2024

Evaluating Ultragenyx Pharmaceutical: Insights From 7 Financial Analysts - Benzinga

Nov 06, 2024

International Assets Investment Management LLC Boosts Stock Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat

Nov 06, 2024

Ultragenyx: Excellent Company, Lackluster Stock (NASDAQ:RARE) - Seeking Alpha

Nov 06, 2024